Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects

被引:22
作者
Swanstrom, R
Bosch, RJ
Katzenstein, D
Cheng, HL
Jiang, HY
Hellmann, N
Haubrich, R
Fiscus, SA
Fletcher, CV
Acosta, EP
Gulick, RM
机构
[1] Univ N Carolina, Ctr AIDS Res, Chapel Hill, NC 27599 USA
[2] Harvard Univ, Sch Publ Hlth, Stat & Data Anal Ctr, Boston, MA 02115 USA
[3] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA
[4] ViroLog Inc, San Francisco, CA USA
[5] Univ Calif San Diego, San Diego, CA 92103 USA
[6] Univ Colorado, Denver, CO 80202 USA
[7] Univ Alabama Birmingham, Birmingham, AL USA
[8] Cornell Univ, Weill Med Coll, New York, NY USA
关键词
D O I
10.1086/422692
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We analyzed retrospectively, by use of logistic regression, the role of the phenotypic susceptibility score (PSS) as a determinant of virologic outcome in a study of treatment-experienced human immunodeficiency virus (HIV) type 1-infected subjects. A model for PSS in which each drug was treated equally and scored as active or inactive was not predictive of HIV-1 RNA load (VL) suppression. However, weighting the potential contribution of each drug on the basis of inferred potency and by use of a continuous scale to quantify drug susceptibility revealed significant associations between PSS and outcome. Entry VL was a strong independent predictor of therapy outcome, and PSS was a strong predictor of the magnitude of the initial decrease in VL. This suggests that the prospective evaluation of PSS to identify regimens that maximize decreases in VL to reduce the probability of virologic rebound could improve antiretroviral treatment.
引用
收藏
页码:886 / 893
页数:8
相关论文
共 47 条
  • [1] A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
    Baxter, JD
    Mayers, DL
    Wentworth, DN
    Neaton, JD
    Hoover, ML
    Winters, MA
    Mannheimer, SB
    Thompson, MA
    Abrams, DI
    Brizz, BJ
    Ioannidis, JPA
    Merigan, TC
    [J]. AIDS, 2000, 14 (09) : F83 - F93
  • [2] BEAL SL, 1992, NONMEM USERS GUIDES
  • [3] STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT
    BLAND, JM
    ALTMAN, DG
    [J]. LANCET, 1986, 1 (8476) : 307 - 310
  • [4] Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection
    Call, SA
    Saag, MS
    Westfall, AO
    Raper, JL
    Pham, SV
    Tolson, JM
    Hellmann, NS
    Cloud, GA
    Johnson, VA
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (03) : 401 - 408
  • [5] Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
    Cameron, DW
    Heath-Chiozzi, M
    Danner, S
    Cohen, C
    Kravcik, S
    Maurath, C
    Sun, E
    Henry, D
    Rode, R
    Potthoff, A
    Leonard, J
    [J]. LANCET, 1998, 351 (9102) : 543 - 549
  • [6] Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen
    Casado, JL
    Moreno, S
    Hertogs, K
    Dronda, F
    Antela, A
    Dehertogh, P
    Perez-Elías, MJ
    Moreno, A
    [J]. AIDS, 2002, 16 (01) : 47 - 52
  • [7] A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy
    Cohen, CJ
    Hunt, S
    Sension, M
    Farthing, C
    Conant, M
    Jacobson, S
    Nadler, J
    Verbiest, W
    Hertogs, K
    Ames, M
    Rinehart, AR
    Graham, NM
    [J]. AIDS, 2002, 16 (04) : 579 - 588
  • [8] Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome
    Deeks, SG
    Hellmann, NS
    Grant, RM
    Parkin, NT
    Petropoulos, CJ
    Becker, M
    Symonds, W
    Chesney, M
    Volberding, PA
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (06) : 1375 - 1381
  • [9] DeGruttola V, 2000, ANTIVIR THER, V5, P41
  • [10] Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy
    Dornadula, G
    Zhang, H
    VanUitert, B
    Stern, J
    Livornese, L
    Ingerman, MJ
    Witek, J
    Kedanis, RJ
    Natkin, J
    DeSimone, J
    Pomerantz, RJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (17): : 1627 - 1632